Paul Riska

2.4k total citations
30 papers, 1.2k citations indexed

About

Paul Riska is a scholar working on Epidemiology, Infectious Diseases and Ecology. According to data from OpenAlex, Paul Riska has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 20 papers in Infectious Diseases and 8 papers in Ecology. Recurrent topics in Paul Riska's work include Tuberculosis Research and Epidemiology (12 papers), Mycobacterium research and diagnosis (12 papers) and Bacteriophages and microbial interactions (8 papers). Paul Riska is often cited by papers focused on Tuberculosis Research and Epidemiology (12 papers), Mycobacterium research and diagnosis (12 papers) and Bacteriophages and microbial interactions (8 papers). Paul Riska collaborates with scholars based in United States, Mexico and France. Paul Riska's co-authors include William R. Jacobs, John Chan, Horatio B. Fung, Marie L. Landry, David Ferguson, David Alland, Susan E. Hattox, Thomas R. MacGregor, Joseph Pav and Michael Lamson and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Clinical Infectious Diseases.

In The Last Decade

Paul Riska

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Riska United States 17 753 636 248 185 148 30 1.2k
J. Kenneth McClatchy United States 26 1.0k 1.4× 1.2k 1.9× 167 0.7× 384 2.1× 226 1.5× 54 1.9k
Lisa Y. Armitige United States 17 676 0.9× 487 0.8× 39 0.2× 240 1.3× 136 0.9× 29 1.0k
Johannes Nemeth Switzerland 19 782 1.0× 586 0.9× 32 0.1× 229 1.2× 350 2.4× 61 1.5k
Nicole J. Moreland New Zealand 25 1.2k 1.6× 411 0.6× 66 0.3× 602 3.3× 51 0.3× 86 2.1k
Keira A. Cohen United States 17 561 0.7× 511 0.8× 176 0.7× 283 1.5× 119 0.8× 20 924
Gesham Magombedze United States 19 571 0.8× 550 0.9× 33 0.1× 172 0.9× 109 0.7× 52 1.1k
J. Carl Craft United States 25 567 0.8× 755 1.2× 27 0.1× 224 1.2× 98 0.7× 46 1.7k
Ting‐Shu Wu Taiwan 20 479 0.6× 442 0.7× 28 0.1× 350 1.9× 140 0.9× 64 1.2k
Jessica Minion Canada 21 1.0k 1.3× 1.2k 1.8× 41 0.2× 130 0.7× 418 2.8× 55 1.6k
Erik Sturegård Sweden 21 728 1.0× 710 1.1× 21 0.1× 177 1.0× 467 3.2× 51 1.2k

Countries citing papers authored by Paul Riska

Since Specialization
Citations

This map shows the geographic impact of Paul Riska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Riska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Riska more than expected).

Fields of papers citing papers by Paul Riska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Riska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Riska. The network helps show where Paul Riska may publish in the future.

Co-authorship network of co-authors of Paul Riska

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Riska. A scholar is included among the top collaborators of Paul Riska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Riska. Paul Riska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Garcia, Elizabeth, Tristan D. McPherson, Maura K. Lash, et al.. (2023). Notes from the Field: Posttreatment Lesions After Tecovirimat Treatment for Mpox — New York City, August–September 2022. MMWR Morbidity and Mortality Weekly Report. 72(17). 471–472. 2 indexed citations
3.
Meyerowitz, Eric A., Inessa Gendlina, Robert Grossberg, et al.. (2022). Anorectal Testing for Mpox Virus Infection in Men Who Have Sex With Men With and Without Proctitis. Clinical Infectious Diseases. 76(5). 934–937. 8 indexed citations
4.
Yoon, Hyunah, et al.. (2021). Unexpected case of cryptococcal meningoencephalitis in a patient with long-standing well-controlled HIV infection. Medical Mycology Case Reports. 32. 14–16. 2 indexed citations
5.
Szymczak, Wendy, Yi Guo, Michael H. Levi, et al.. (2018). Two for the price of one: emerging carbapenemases in a returning traveller to New York City. BMJ Case Reports. 2018. bcr–2018. 14 indexed citations
6.
7.
Ostrowsky, Belinda, Rafael Azuar Ruíz, Philip Chung, et al.. (2014). Lessons Learned from ImplementingClostridium difficile–Focused Antibiotic Stewardship Interventions. Infection Control and Hospital Epidemiology. 35(S3). S86–S95. 13 indexed citations
8.
Guha, Malini, et al.. (2013). Toxocariasis presenting as eosinophilic ascites in a post-partum female. Journal of Parasitic Diseases. 39(2). 284–286. 5 indexed citations
9.
Boyanton, Bobby L., et al.. (2011). Loop-Mediated Isothermal Amplification Compared to Real-Time PCR and Enzyme Immunoassay for Toxigenic Clostridium difficile Detection. Journal of Clinical Microbiology. 50(3). 640–645. 49 indexed citations
10.
Kohlhoff, Stephan, Andrei Kutlin, Paul Riska, et al.. (2007). In vitro models of acute and long-term continuous infection of human respiratory epithelial cells with Chlamydophila pneumoniae have opposing effects on host cell apoptosis. Microbial Pathogenesis. 44(1). 34–42. 3 indexed citations
11.
Fung, Horatio B., et al.. (2006). Tigecycline: A glycylcycline antimicrobial agent. Clinical Therapeutics. 28(8). 1079–1106. 121 indexed citations
12.
Riska, Paul, et al.. (2004). Genetic and Culture-Based Approaches for Detecting Macrolide Resistance inChlamydia pneumoniae. Antimicrobial Agents and Chemotherapy. 48(9). 3586–3590. 10 indexed citations
13.
Riska, Paul & William R. Jacobs. (2003). The Use of Luciferase-Reporter Phage for Antibiotic-Susceptibility Testing of Mycobacteria. Humana Press eBooks. 101. 431–456. 26 indexed citations
14.
Bardarov, Svetoslav, K. D. Eisenach, Niaz Banaiee, et al.. (2003). Detection and drug-susceptibility testing of M. tuberculosis from sputum samples using luciferase reporter phage: comparison with the Mycobacteria Growth Indicator Tube (MGIT) system. Diagnostic Microbiology and Infectious Disease. 45(1). 53–61. 44 indexed citations
15.
Hazbón, Manzour Hernando, Beatriz E. Ferro, Ana Lucía Rodríguez-Perea, et al.. (2003). Photographic and Luminometric Detection of Luciferase Reporter Phages for Drug Susceptibility Testing of Clinical Mycobacterium tuberculosis Isolates. Journal of Clinical Microbiology. 41(10). 4865–4869. 41 indexed citations
16.
Hill, A. Ross, et al.. (2002). Effectiveness of Directly Observed Therapy (DOT) for Tuberculosis. Medicine. 81(3). 179–193. 15 indexed citations
17.
Riska, Paul & Stephen Carleton. (2002). Latent tuberculosis: Models, mechanisms, and novel prospects for eradication. Seminars in Pediatric Infectious Diseases. 13(4). 263–272. 10 indexed citations
18.
Riska, Paul, Michael Lamson, Thomas R. MacGregor, et al.. (1999). Disposition and Biotransformation of the Antiretroviral Drug Nevirapine in Humans. Drug Metabolism and Disposition. 27(8). 895–901. 174 indexed citations
19.
Glatman‐Freedman, Aharona, Jean Martin, Paul Riska, Barry R. Bloom, & A. Casadevall. (1996). Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. Journal of Clinical Microbiology. 34(11). 2795–2802. 61 indexed citations
20.
Skehel, J.J., David S. Burt, R. S. Daniels, et al.. (1989). Immune recognition of influenza virus haemagglutinin. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 323(1217). 479–485. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Kenneth McClatchy Breakdown of academic impact, for papers by Lisa Y. Armitige Breakdown of academic impact, for papers by Johannes Nemeth Breakdown of academic impact, for papers by Nicole J. Moreland Breakdown of academic impact, for papers by Keira A. Cohen Breakdown of academic impact, for papers by Gesham Magombedze Breakdown of academic impact, for papers by J. Carl Craft Breakdown of academic impact, for papers by Ting‐Shu Wu Breakdown of academic impact, for papers by Jessica Minion Breakdown of academic impact, for papers by Erik Sturegård
Rankless by CCL
2026